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Determination of the prevalence of hemoglobin S, C, D, and G in
neonates from Buenaventura, Colombia*
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SUMMARY
Introduction: Inherited hemoglobinopathies are common among African Blacks. In Buenaventura, a city on Colombia’s
Pacific coast, where 92% of the population is Afro-Colombian, there are few published attempts to identify these disorders.
Affected individuals require more health care due to higher morbidity and mortality. Early identification of these newborns
followed by comprehensive care is important to reduce co-morbidities.
Objective: To study newborns and establish the numbers at risk with a bloodspot screening method. This information
will demonstrate to Public Health Authorities the need to provide care  for this  population.
Methods: A cross-sectional descriptive study of a sample of 399 newborns (95% CI) where there is an expected prevalence
of 10% of abnormal hemoglobins. Mothers in at least the 36th week of gestation, living in  the urban area of Buenaventura,
were used. Umbilical cord blood was drawn and specimens fixed on filter paper and stored at 4°C. Isoelectric focusing
electrophoresis assays were used to separate the hemoglobins. The results were reported according to the identified
hemoglobin as F, A, S, C, D, and G.
Results: We processed 399 samples, 353 (88.5%) were normal (hemoglobin FA), 23 (5.8%) were heterozygous for
hemoglobin C (FAC), 19 (4.8%) were heterozygous for hemoglobin S (FAS), 2 (0.5%) were heterozygous for hemoglobin
G (FAG), 1 was heterozygous for hemoglobin D (FAD) and 1 was heterozygous combined S and C (FSC).
Conclusion: Hemoglobins S, C, D, and G are common among infants born in Buenaventura. Hemoglobin C occurred
more frequently than in other reported studies. This study  suggests that both detection and a follow-up program are
required in areas with a high density of Afro-Colombian population.
Keywords: Prevalence; Newborn; Hemoglobinopathies; Hemoglobin S; Hemoglobin C; Anemia;
Sickle cell; Electrophoresis, iso electric point; Colombia.
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RESUMEN
Introducción: Las hemoglobinopatías son entidades muy frecuentes en el África negra. En Buenaventura, ciudad de la
costa pacífica colombiana con una población 92% afrocolombiana, hay pocas publicaciones identificando esta patología. Las
poblaciones afectadas requieren cuidados especiales por su alta mortalidad y morbilidad. La identificación temprana desde
el periodo neonatal y los programas de cuidado integral se imponen en poblaciones de alta prevalencia.
Objetivo: Determinar la prevalencia en Buenaventura de hemoglobinas S, C, D y G con un modelo de tamizaje neonatal.
La información colectada servirá para sustentar recomendaciones a las autoridades de salud pública.
Metodología: Se realizó un estudio descriptivo de corte transversal en 399 neonatos para una prevalencia esperada del
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10% (IC 95%), con madres residentes del área urbana de
Buenaventura y 36 semanas o más de gestación. Se tomó
muestra de sangre de cordón umbilical fijada en papel filtro y
almacenada a 4°C. La técnica de electroforesis de punto
isoeléctrico sirvió para la separación de las hemoglobinas.
Los resultados se informaron de acuerdo a las hemoglobinas
identificadas F, A, S, C, D y G.
Resultados: Se procesaron 399 muestras de cordón. El
88.5% (353) de las muestras fueron normales (hemoglobina
FA), 23 (5.8%) fueron heterocigotos para hemoglobina C
(FAC), 19 (4.8%) fueron heterocigotos para hemoglobina S
(FAS), 2 (0.5%) fueron heterocigotos para hemoglobina G
(FAG), 1 fue heterocigoto para hemoglobina D (FAD) y 1 fue
heterocigoto combinado S y C (FSC).
Conclusión: Hemoglobinas S, C, D y G son frecuentes
entre los neonatos de Buenaventura. La hemoglobina C fue
más frecuente que en estudios previos, probablemente por
sesgos en la selección de la muestra de dichos estudios. Se
sugiere a las autoridades de salud pública la ampliación del
programa de tamizaje de enfermedades congénitas como las
hemoglobinopatías.
 Palabras clave: Prevalencia; Recién nacido;
Hemoglobina S; Hemoglobina C; Anemia de células
falciformes; Electroforesis de punto isoeléctrico;
Colombia; Hemoglobinopatías.
Neonatal screening for abnormal hemoglobin (Hb)
permits establishing the presence of hemoglobinopathies
in the population. Sickle-cell disease is one of these, with
the disorder being most frequent in countries with obligatory
neonatal screening1,2. It is produced by the specific mutation
of the beta-globin gene3, resulting from the change of
glutamic acid for valine in the 6th position, of autosomal
recessive inheritance. The most common genotypes are:
homozygous hemoglobin S (HbS), combined heterozy-
gous SC (HbSC), and Sβ+ thalassemia and Sβ0 thalassemia;
and, less frequently, it is due to the combination of hemoglobin
S with other variants (for example, hemoglobin D, G).
Sickle-cell disease increases morbidity and mortality
during the first years of life4, being greater in homozygous
SS individuals in comparison to heterozygous SC.
Hemoglobin C is associated to less symptoms and offers
protection against severe malaria5.
The high prevalence of sickle-cell anemia in a
population with African ancestry was shown in the
analysis of records from Texas from 1992 to 1998, from
2’292,698 live births and 94% specimens collected,
revealing total prevalence per ethnic groups per every
10,000 live births of 29.91 Afro-Americans, 0.11 White,
0.29 Hispanic, and 2.47 others6. The studies conducted
in the city of Buenaventura and in other towns in the
Colombian Pacific region are: from a reference center
for malaria infection in individuals older than one year of
age that showed a prevalence of 14.9% of abnormal
hemoglobins (AS of 7%, AC of 6.2%, and AD of
1.7%)7; from the Hematology service at Universidad
del Valle in individuals referred because of having
samples suspicious of sickle-cell anemia8, and from
Salahonda (close to Tumaco in Nariño, Colombia) with
sickle-cell trait in 10% of the population and clinical
relevant hemoglobinopathies by 1%9.
A preliminary report published in 2004 of neonatal
screening begun in Cali (Valle del Cauca, Colombia, with
an Afro-Colombian population of 26.51%) as of 2003 of
6500 neonates, revealed 146 cases of HbS carriers (2.4%),
90 cases heterozygous HbC (1.4%), 2 heterozygous HbD
(0.02%), and 2 homozygous HbC, without cases of
homozygous S10; however, there is no definition of
inclusion criteria (especially of gestational age) and of
exclusion criteria (transfusions prior to taking the sample).
There is no knowledge of the prevalence of the types of
abnormal hemoglobins (S, C, D, and G) in newborns in the
city of Buenaventura (Valle del Cauca, Colombia). This
city, located in the Pacific region, has a population
projected for 2005 of 278,960 inhabitants (86% living in the
urban zone)11. The proportion of Afro-Colombian population
is of 92%. Previous studies of cost-effectiveness analysis
favor neonatal detection aimed at, that is, only newborns
from some ethnic groups12,13 when the individuals at risk
are few among the population; however, universal detection
identifies more newborns with the disease and prevents
more deaths14,15.
Early detection of homozygous S newborns permits
the application of broadly recognized integral programs
in health services, vaccines, monitoring, and education
for children and their parents2, diminishing the incidence
of infection and associated mortailty16. Parent education
on disease and above all the symptoms (e.g., splenic
sequestration) permits opportune attention of severe
cases. The possibility of curing via allogenic stem cell
transplants informed in the literature, although still
promissory, assigns more relevance to detection17.
The objective of this study was to determine the
prevalence of hemoglobins S, C, D, and G in newborns
from a high-risk zone like the city of Buenaventura.
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METHODS
A descriptive cross-sectional study was conducted.
Universal screening was employed15.
To estimate the sample size, we used the information
on the projected population for the city of Buenaventura
for 2005, because the data for the 2005 census and
projections for subsequent years had not been
published18. Said projection reports 278,960 inhabitants
(86% located in the urban zone)11. To estimate the
sample size, the StatCalc 6 th version program by EpiInfo
was used based on the following considerations:
estimated prevalence of hemoglobinopathies (S, C, D,
G) equal to 10%9, margin of error of 3%, and confidence
level of 95%. The representative minimum sample size
was of 384 newborns.
The samples were taken from newborns at three
hospitalization centers in the city: Departmental Hospi-
tal of Buenaventura – complexity level 2, Luis Ablanque
de la Plata Hospital – complexity level 1, and the
Buenaventura Clinic – complexity level 2 (these are the
hospitalization centers in Buenaventura authorized for
childbirth attention by the Valle del Cauca Departmental
Secretary of Public Health), these were taken after
informed signed consent by legal guardians.
Inclusion criteria. Gestational age of 36 or more
weeks (corroborated by obstetric sonogram, given that
more premature newborns do not express in adequate
proportion the hemoglobins of the adult stage19), domiciled
in the urban area of Buenaventura, born between 01
February 2007 and 01 February 2008. On an adjoining
card, the following data were registered: mother’s name
(or legal guardian), mother’s age (in years), telephone
number, home address, gestational age, date of birth,
sex (female or male), and weight of the newborn.
Exclusion criteria: newborns with red blood cell
transfusion prior to taking the sample.
Taking of blood sample and storage.  Using a
syringe, 1 ml of blood was drawn from the umbilical cord
placental end in loop form after its ligation (or from the
heel, in case of not having been obtained from the first
site or due to bad previous sample taking) and a drop
was fixed on each circle of the filter paper (a total of 4
drops), and stored at 4ºC.
Analytical methods.  The isoelectric focusing
electrophoresis (IFE) technique was selected because
of the low costs of equipment and samples, high sensitivity
(100%), and specificity (100%) compared to methods
like electrophoresis in cellulose agar and high-perfor-
mance liquid chromatography20 with low intra- and
inter-assay error21, permitting reproduction of the results.
With IFE, each hemoglobin has a defined isoelectric
point (pI) (Table 1). To develop the methodology, we
used the Wallac RESOLVE® Neonatal Hemoglobin
test kit (PerkinElmer, 940 Winter Street, Waltham,
Massachusetts 02451, USA)21,22.
The results of the hemoglobins were reported in
qualitative order according to the percentage of hemo-
globins present like: FA (normal), FS (homozygous Hb
S), FAS (carrier Hb S), FC (homozygous Hb C), FAC
(carrier Hb C), FSC (mixed S and C heterozygous),
FAD (carrier Hb D), and FAG (carrier Hg G) (Graph 1).
The statistical analysis was conducted based on
percentage distributions, prevalence, and confidence
intervals of 95% - according to the exact binomial
method using the Epi Info Software for Windows,
version 3.3.2.
Ethical considerations. The study was approved
by the Institutional Committee on Human Ethics Review
of the Faculty of Health at Universidad del Valle. The
sample was taken from each newborn after informed
signed consent from one of the parents or legal guardian.
RESULTS
In total, 399 samples were collected from newborns
at three Institutions: Departmental Hospital of Buena-
ventura 252 (63.2%), Luis Ablanque de Plata Hospital
113 (28.3%), and Buenaventura Clinic 34 (8.5%). Some
98.7% of the samples were taken from the umbilical
cord; the rest were collected from the heel.
Table 1
Isoelectric points  (pI) of the hemoglobin variants.
Resolve Isoscan (Perkin–Elmer) system
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A total of 50.6% of the newborns were females. The
average gestational age was 39.3 ± 1.1 weeks, with
average weight at birth of 3114 ± 505 g. The prevalence
of newborns with at least one abnormal hemoglobin was
of 11.7%, with 8.6%-15.1% having a confidence interval
of 95% (Table 2, Graph 2, Graph 3, Graph 4). No
significant statistical differences were found regarding
gender or the gestational age of the newborns with
respect to the hemoglobin pattern.
Graph 1. Hemoglobin isoelectric focusing electrophoresis
Pattern: reference pattern. FAS: heterozygous hemoglobin S. FAC: heterozygous hemoglobin C. FA: normal. Sample processed in the
Endocrine Laboratory at Universidad del Valle.
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Sample processed in the Endocrine Laboratory at Universidad del  Valle
Graph 3. Identification
of the heterozygous
hemoglobin D via iso-
electric focusing elec-
trophoresis
Graph 2.  Identification of
the heterozygous hemo-
globin G via isoelectric
focusing electrophoresis
Graph 4. Identification of combined heterozygous
SC via isoelectric focusing electrophoresis
146
Colombia Médica                  Vol. 41 Nº 2, 2010 (Abril-Junio)
DISCUSSION
Although the total percentage of abnormal hemo-
globins in this study is similar to prior studies7-9, we note
a greater proportion of newborns with hemoglobin C, in
comparison with previous studies in the zone. Hemoglobin
C is more frequent in Western Africa23 and it is associated
to minor symptoms related to malaria infection5,24.
Homozygous C has lower complications related to
sickle-cell anemia when compared to homozygous S.
They may even be asymptomatic into adulthood, although
the retinopathy related to sickle-cell anemia is more
frequent with hemoglobin C25, requiring periodic ophthal-
mologist control of these individuals.
The previously mentioned studies conducted in adults
and children older than one year of age could under-
estimate the prevalence in the population when not
including the children who perished because of sickle-
cell disease before reaching one year of life, and not
including individuals with hemoglobin C that may not
have attended the center of reference for malaria
infection (because of manifesting few or no symptoms).
Only one newborn with combined heterozygous SC
was found, warranting a periodic monitoring. In these
individuals, it was not establish the effectiveness of the
antibiotic prophylaxis to diminish mortality due to
pneumococcus, which has indeed benefited homozygous
SS individuals. The current study found no homozygous
S or C, given that the design was not made for individuals
with the disease of sickle-cell anemia; this requires a
larger sample size. When the screening detects a newborn
with hemoglobins FS or FC, the test must be confirmed
before two months of age to discard the co-existence of
beta+ thalassemia26. In 2007, 4546 babies were born in
the urban zone of Buenaventura27. The study sample of
399 newborns represents 8.7% (399/4546) of the live
births for 2007, hence, applying for this period.
The high prevalence of hemoglobin alterations in a
high-risk population, like Buenaventura, suggests the
need for an universal neonatal detection program in
these types of zones. This should be done for the
purpose of early detection of homozygous S or C
individuals, and opportunely initiate preventive and
educational measures tending to diminishing morbidity
and mortality related to sickle-cell anemia.
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